• ALX Oncology entered a secured multi-tranche term loan facility of up to USD 50 million with HSBC Ventures USA on June 25, 2026.
• USD 10 million was drawn at closing to refinance the prior Oxford Finance and Silicon Valley Bank facility, covering related fees.
• USD 20 million remains available to draw through June 30, 2028; another USD 10 million depends on Phase 2 ASPEN-09 and ALX2004 safety milestones.
• Up to USD 10 million is available at the lender’s sole discretion; proceeds may be used for general corporate purposes.
• Loans mature June 1, 2030; pricing is floating at the greater of Prime or 6%; collateral covers substantially all assets with an IP negative pledge.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-285425), on June 26, 2026, and is solely responsible for the information contained therein.